This mechanism expands on the previously established mechanisms by which LMP1 regulates miR-155 and FOXO3a and may represent both rational therapeutic targets and biomarkers for EBV+ B cell lymphomas. This evidence concerns the gene FOXO3 and B-cell non-Hodgkin lymphoma.